FLC Capital Advisors Invests $176,000 in Takeda Pharmaceutical Co. $TAK

FLC Capital Advisors acquired a new position in shares of Takeda Pharmaceutical Co. (NYSE:TAK) in the second quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 11,372 shares of the company’s stock, valued at approximately $176,000.

A number of other hedge funds also recently made changes to their positions in the stock. GAMMA Investing LLC grew its stake in Takeda Pharmaceutical by 22.6% during the first quarter. GAMMA Investing LLC now owns 7,042 shares of the company’s stock worth $105,000 after purchasing an additional 1,296 shares during the period. Allspring Global Investments Holdings LLC grew its stake in Takeda Pharmaceutical by 5.4% during the first quarter. Allspring Global Investments Holdings LLC now owns 21,373 shares of the company’s stock worth $319,000 after purchasing an additional 1,098 shares during the period. Farther Finance Advisors LLC grew its stake in Takeda Pharmaceutical by 29.2% during the first quarter. Farther Finance Advisors LLC now owns 4,620 shares of the company’s stock worth $69,000 after purchasing an additional 1,045 shares during the period. Vontobel Holding Ltd. acquired a new stake in Takeda Pharmaceutical during the first quarter worth approximately $262,000. Finally, Cerity Partners LLC grew its stake in Takeda Pharmaceutical by 81.7% during the first quarter. Cerity Partners LLC now owns 159,285 shares of the company’s stock worth $2,369,000 after purchasing an additional 71,634 shares during the period. 9.17% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

TAK has been the subject of several recent analyst reports. Weiss Ratings reaffirmed a “hold (c+)” rating on shares of Takeda Pharmaceutical in a research note on Tuesday, October 14th. Zacks Research cut Takeda Pharmaceutical from a “hold” rating to a “strong sell” rating in a research note on Thursday, August 21st. One research analyst has rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, Takeda Pharmaceutical presently has a consensus rating of “Hold”.

Takeda Pharmaceutical Trading Up 0.2%

Shares of Takeda Pharmaceutical stock opened at $14.07 on Tuesday. The stock has a market capitalization of $44.75 billion, a PE ratio of 46.88 and a beta of 0.21. The company has a debt-to-equity ratio of 0.60, a quick ratio of 0.59 and a current ratio of 1.16. Takeda Pharmaceutical Co. has a 52 week low of $12.80 and a 52 week high of $15.69. The stock has a 50 day moving average price of $14.81 and a two-hundred day moving average price of $14.75.

Takeda Pharmaceutical (NYSE:TAK) last announced its quarterly earnings results on Wednesday, July 30th. The company reported $0.52 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.47 by $0.05. Takeda Pharmaceutical had a return on equity of 10.50% and a net margin of 3.20%.The business had revenue of $7.45 billion during the quarter, compared to the consensus estimate of $7.96 billion. Takeda Pharmaceutical has set its FY 2025 guidance at 3.360-3.360 EPS. As a group, equities analysts anticipate that Takeda Pharmaceutical Co. will post 1.64 earnings per share for the current fiscal year.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.